Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response

Phase 4

Completed

• Conditions: Gastroesophageal Reflux

• Registration Number: NCT00392002
• Lead Sponsor: AstraZeneca

Brief Summary

To characterize the burden of disease in GERD patients of prescription therapy'

Detailed Description

Not available

Study Timeline

• Study Start: 2005-10
• Study First Submitted: 2006-10-24
• Study First Submitted QC: 2006-10-24
• Study First Posted: 2006-10-25
• Study Completion: 2007-05
• Status Verified: 2008-01
• Last Update Submitted: 2008-01-24
• Last Update Posted: 2008-01-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 2000

Inclusion Criteria

• Signed informed consent, 18 years or older, diagnosis of GERD

Exclusion Criteria

• Peptic ulcer disease, upper gastrointestinal surgery, malignancy

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Primary Outcome Measures

Name	Time	Method
To compare the improvement in burden of overall GERD symptoms after 4 weeks of treatment with Esomeprazole verses maintenance of current therapy in subjects with persistent GERD symptoms.

Secondary Outcome Measures

Name	Time	Method
To examine the relationship of the severity and frequency of GERD symptoms to treatment, at national, and regional levels.

Trial Locations

Locations (1)

Research Site; 🇨🇦 Toronto, Ontario, Canada